Skip to content

Media Release, February 9, 2011


Alliance Recognizes Imperative for Budget-Cutting; Views FDA as an Exception

WASHINGTON, D.C., February 9, 2011 – The Alliance for a Stronger FDA today responded with concern to the House Appropriations Committee’s announcement of cuts to FDA that will be included in that body’s FY 11 Continuing Resolution (CR). The CR will be considered on the House floor next week.

“Our nation needs an effective FDA, which requires continuing increases for an agency that has been chronically underfunded for several decades,” said Nancy Bradish Myers, President of the Alliance for a Stronger FDA and President of Catalyst Healthcare Consulting. “We certainly understand the need to reduce the federal budget, but want to be sure that Congress has a clear picture of how FDA contributes to economic growth and national security, as well as protecting our public health.”

The committee is proposing that FDA be cut by $220 million below the President’s request level for FY 11. The amount is about $74 million less than FY 10 funding, which is the level at which the agency has received and spent funds thus far in FY 11.

“FDA touches every American multiple times each day through its jurisdiction over drugs, biologics, medical devices, 80 % of the food supply, cosmetics, dietary supplements and varied consumer products. Altogether, the agency oversees nearly 25% of consumer spending in the United States,” said Margaret Anderson, Vice President of the Alliance and Executive Director of FasterCures. “FDA funding should reflect that the agency’s responsibilities and workload increase each year–through globalization, scientific complexity, and the growth of industry, as well as through new mandates.”

Ms. Myers added: “Today’s investment of 2 cents per American per day is small compared to the benefits of a strong FDA and the risks from an underfunded FDA. We look forward to working further with Congress to be sure that the needs of the American people are being met.”

The Alliance’s 180 (and growing) membership is comprised of consumer, patient, professional and research groups, companies, trade associations, and individuals who support increased appropriated funding for FDA.  The Alliance is the only multi-stakeholder group that advocates for increasing resources at FDA to match the agency’s responsibilities.

More information about the Alliance can be found at